Use of Crotalidae equine immune F(ab’)2 antivenom for treatment of an Agkistrodon envenomation

B. Z. Wilson, J. Larsen, G. Smelski, S. Dudley, F. M. Shirazi

Research output: Contribution to journalArticlepeer-review


Introduction: Anavip (F(ab’)2AV) is a lyophilized F(ab’)2 immunoglobulin fragment derived from horses immunized with venom from Bothrops asper and Crotalus durissus. It was approved by the FDA in 2015 for treatment of North American rattlesnake envenomation but not for Agkistrodon envenomation. Published data regarding the efficacy and safety of Anavip in treating Agkistrodon envenomations is limited. We present a case of a patient treated with Anavip after confirmed Agkistrodon laticinctus envenomation. Case details: A 77 year-old man was bitten on his fifth finger by a captive A. laticinctus. He was taken to a local emergency department where he received a 10 vial initial dose of F(ab’)2AV for pain and swelling and was transferred. At the receiving facility, his pain had improved and his swelling had not progressed. Over the next 30 h, his platelets declined to 132,000/mm3 and he received an additional 4 vials of F(ab’)2AV. The remainder of his course was unremarkable with complete recovery by 3 months. Discussion: This case provides an additional published datapoint on the use of this F(ab’)2AV in the treatment of envenomation by Agkistrodon.

Original languageEnglish (US)
Pages (from-to)1023-1026
Number of pages4
JournalClinical Toxicology
Issue number11
StatePublished - 2021


  • Agkistrodon
  • Anavip
  • Antivenins
  • Snakes

ASJC Scopus subject areas

  • Toxicology


Dive into the research topics of 'Use of Crotalidae equine immune F(ab’)2 antivenom for treatment of an Agkistrodon envenomation'. Together they form a unique fingerprint.

Cite this